Rani Therapeutics names Nicholas Maestas as new chief financial officer

Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas M. Maestas as the Company's Chief Financial Officer, serving as principal financial officer and principal accounting officer, effective as of June 29, 2026.¹ Mr. Maestas succeeds Svai Sanford, who the company had previously said would be stepping down once a successor was named.¹

Maestas, 46, most recently served as Chief Financial Officer and Head of Corporate Strategy of Tempest Therapeutics, Inc. from January 2025 until June 2026, after previously serving as Vice President, Finance and Strategy at Tempest from July 2021 through December 2024, and as its Corporate Secretary since September 2022.¹ Earlier in his career, he served as head of FP&A and strategic finance at Alector, a biopharmaceutical company, from July 2019 to July 2021.¹ Before that, he held several roles at Immune Design, an oncology immunotherapy company acquired by Merck & Co in 2019, including Senior Director, Corporate Development & Operations from January to July 2019, and Director, Corporate Development & Operations from January 2017 to December 2018.¹ He holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and an M.B.A. from The Wharton School, University of Pennsylvania.¹

Under his offer letter dated June 24, 2026, Maestas will receive an annual base salary of $500,000 and will be eligible for an annual bonus targeted at 75% of his base salary.¹ He will also be granted a non-qualified option to purchase 2,000,000 shares of the Company's Class A common stock under the Company's 2026 Equity Inducement Plan.¹ The option vests over four years, with 25% vesting after one year and the remainder vesting equally over the following 36 months of continuous service.¹

Separately, the Company's Board of Directors approved the 2026 Equity Inducement Plan on June 28, 2026, reserving 5,500,000 shares of Class A common stock for inducement awards to new hires.¹